Evidence map›Paper›PMID 36402457›Full record

ArticleTransplantation and cellular therapy2023

Hematopoietic Stem Cell Transplantation Activity in China 2020-2021 During the SARS-CoV-2 Pandemic: A Report From the Chinese Blood and Marrow Transplantation Registry Group.

Lan-Ping Xu, Dao-Pei Lu, De-Pei Wu, Er-Lie Jiang, Dai-Hong Liu, He Huang, Zi-Min Sun, Nai-Nong Li, Qi-Fa Liu, Xi Zhang and 14 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation and cellular therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. A donor PD-1Signal transduction and targeted therapy · 2025
    Article
  9. Article
  10. Review
  11. [Progress in hematopoietic stem cell transplantation for acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025
    Review
  12. Article
  13. Quality-adjusted time without symptoms or toxicity analysis of haploidentical-related donorChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 18 institutions in 1 country.

Lan-Ping XuPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Dao-Pei LuHebei Yanda Lu Daopei Hospital & Beijing Ludaopei Hospital, Langfang, Hebei & Beijing, China.
De-Pei WuThe First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Disease, Soochow, China.
Er-Lie JiangBlood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
Dai-Hong LiuChinese PLA General Hospital, Beijing, China.
He HuangThe First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zi-Min SunThe First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
Nai-Nong LiFujian Medical University Union Hospital, Fujian Provincial Key Laboratory of Hematology, Fujian Institute of Hematology, Fuzhou, China.
Qi-Fa LiuNanfang Hospital, Guangzhou, China.
Xi ZhangXinqiao Hospital of Army Medical University, Chongqing, China.
Yong-Rong LaiThe First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Yong-Ping SongHenan Cancer Hospital, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Xian-Min SongShanghai General Hospital, Shanghai, China.
Si-Xi LiuShenzhen Children's Hospital, Shenzhen, China.
Yi-Cheng ZhangTongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
Cheng-Juan LuoShanghai Children's Medical Center, Shanghai, China.
Ling-Hui XiaUnion Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
Ting NiuWest China Hospital, Sichuan University, Chengdu, China.
Yu YuPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Xiao-Hui ZhangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Xiao-Wen TangThe First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Disease, Soochow, China.
Yi LuoThe First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xiao-Jun HuangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. Electronic address: huangxiaojun@bjmu.edu.cn.
Chinese Blood and Marrow Transplantation Registry Group
Peking University · CNArmy Medical University · CNShanghai Children's Medical Center · CNSoochow University · CNBeijing Dao Pei Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNChinese PLA General Hospital · CNFirst Affiliated Hospital Zhejiang University · CNFujian Medical University · CNGuangxi Medical University · CNNanfang Hospital · CNShanghai First People's Hospital · CNShenzhen Children's Hospital · CNSichuan University · CNTongji Hospital · CNUniversity of Science and Technology of China · CNWuhan Union Hospital · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Between 2020 and 2021, 31,525 hematopoietic stem cell transplantations (HSCTs) were reported to the Chinese Blood and Marrow Transplantation Registry Group throughout mainland China. In this report, we describe the activity and current trends for HSCT in China during the SARS-CoV-2 pandemic. In 2020, a total of 13,415 cases of HSCT were reported from 166 transplantation teams, and 75% (10,042 cases) were allogeneic HSCTs. In 2021, a total of 18,110 cases of HSCT were reported from 174 transplantation teams, and 70% (12,744 cases) were allogeneic HSCTs. Haploidentical donor (HID) transplantation accounted for 63% (7977 cases) of allogeneic HSCTs in 2021. The most common indications for allogeneic HSCT for malignant disease were acute myeloid leukemia (37%) and acute lymphoblastic leukemia (23%), and the largest proportion of nonmalignant disease comprised aplastic anemia (13%). The peripheral blood stem cell source accounted for 41% of HIDs and 75% of matched sibling donors. The BuCy-based regimen (57%) was the most popular conditioning regimen for allogeneic HSCT, followed by the BuFlu-based regimen (28%) and total body irradiation-based regimen (11%). This survey provides comprehensive information about the current activities and might benefit clinical physicians' decision planning for HSCT.

Indexed as

COVID-19Hematopoietic Stem Cell TransplantationBone MarrowEast Asian PeopleHumansPandemicsRegistriesSARS-CoV-2Hematopoietic stem cell transplantationsSARS-CoV-2 pandemicSurvey

Identifiers

PMID36402457
PMCPMC9671625
OpenAlexW4309508040

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.